Mini Review
|
Open Access
Featured
-
-
Mini Review
| Open AccessBeyond BRAF: where next for melanoma therapy?
- I V Fedorenko
- , G T Gibney
- & K S M Smalley
-
Molecular Diagnostics
| Open AccessBRAFV600E melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity
- C A Whipple
- & C E Brinckerhoff
-
Translational Therapeutics
| Open AccessFunctional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle
- K A Mirza
- & M J Tisdale
-
Translational Therapeutics
| Open AccessTargeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
- M V Gammons
- , R Lucas
- & D O Bates
-
Translational Therapeutics
| Open AccessCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
- M S Carlino
- , L E Haydu
- & G V Long
-
Epidemiology
| Open AccessEpidemiology of basal cell carcinoma in the United Kingdom: incidence, lifestyle factors, and comorbidities
- D Reinau
- , C Surber
- & C R Meier
-
Molecular Diagnostics
| Open AccessDirect T cell–tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme
- P Jin
- , S Civini
- & D Stroncek
-
Translational Therapeutics
| Open AccessProteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
- A Azimi
- , M Pernemalm
- & C Hertzman Johansson
-
Molecular Diagnostics
| Open AccessPotent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion
- G Jiang
- , C-S Yang
- & Y-Q Liu
-
Mini Review
| Open AccessMechanism and consequences of RAF kinase activation by small-molecule inhibitors
- M Holderfield
- , T E Nagel
- & D D Stuart
-
Clinical Study
| Open AccessIpilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
- V Chiarion-Sileni
- , J Pigozzo
- & M Del Vecchio
-
Epidemiology
| Open AccessCumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women
- S Wu
- , J Han
- & A A Qureshi
-
Letter to the Editor
| Open AccessComment on ‘Strong reduction of AGO2 expression in melanoma and cellular consequences’
- M Sand
- , D Georgas
- & F G Bechara
-
Letter to the Editor
| Open AccessReply to comment on: strong reduction of AGO2 expression in melanoma and cellular consequences
- D Völler
- & A Bosserhoff
-
Clinical Study
| Open AccessLow-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients
- C Posch
- , F Weihsengruber
- & K Rappersberger
-
Clinical Study
| Open AccessProkineticins and Merkel cell polyomavirus infection in Merkel cell carcinoma
- S Lauttia
- , H Sihto
- & H Joensuu
-
Letter to the Editor
| Open AccessIntra-patient heterogeneity of BRAF mutation status: fact or fiction?
- A M Menzies
- , J S Wilmott
- & R A Scolyer
-
Epidemiology
| Open AccessStatin use is not associated with reduced risk of skin cancer: a meta-analysis
- X Li
- , X B Wu
- & Q Chen
-
Genetics and Genomics
| Open AccessKey differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling
- S R Lambert
- , N Mladkova
- & C A Harwood
-
Molecular Diagnostics
| Open AccessMutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
- L Heinzerling
- , M Baiter
- & R Schneider-Stock
-
Molecular Diagnostics
| Open AccessExpression of nuclear survivin in normal skin and squamous cell carcinoma: a possible role in tumour invasion
- K Dallaglio
- , T Petrachi
- & C Pincelli
-
Molecular Diagnostics
| Open AccessRole of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion
- S Khosravi
- , R P C Wong
- & G Li
-
Genetics and Genomics
| Open AccessStrong reduction of AGO2 expression in melanoma and cellular consequences
- D Völler
- , J Reinders
- & A-K Bosserhoff
-
Molecular Diagnostics
| Open AccessING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients
- J Lu
- , Y Tang
- & G Li
-
Molecular Diagnostics
| Open AccessCXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
- D Bedognetti
- , T L Spivey
- & F M Marincola
-
Clinical Study
| Open AccessPhase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
- R Plummer
- , P Lorigan
- & H Calvert
-
Epidemiology
| Open AccessPoor oral hygiene and risk of esophageal squamous cell carcinoma in Kashmir
- N A Dar
- , F Islami
- & P Boffetta
-
Clinical Study
| Open AccessKIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
- A Zebary
- , M Jangard
- & J Hansson
-
Molecular Diagnostics
| Open AccessInducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78
- S Martin
- , H K Lamb
- & C P F Redfern
-
Short Communication
| Open AccessTERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
- K G Griewank
- , R Murali
- & M Zeschnigk
-
Molecular Diagnostics
| Open AccessRon tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma
- J Keller
- , A S Nimnual
- & E L Chan
-
Clinical Study
| Open AccessQ-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
- B Sherrill
- , J Wang
- & K Chin
-
Short Communication
| Open AccessPatient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11
- A E Koopmans
- , J Vaarwater
- & A de Klein
-
Molecular Diagnostics
| Open AccessBiological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma
- G Halec
- , D Holzinger
- & M Pawlita
-
Epidemiology
| Open AccessGeography of non-melanoma skin cancer and ecological associations with environmental risk factors in England
- B W Wheeler
- , G Kothencz
- & A S Pollard
-
Epidemiology
| Open AccessThe impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987–2009: a registry-based cohort study
- A F Grann
- , T Frøslev
- & T L Lash
-
Clinical Study
| Open AccessPhase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- M Millward
- , C Underhill
- & C B Mather
-
Genetics and Genomics
| Open AccessRare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
- L Heinzerling
- , S Kühnapfel
- & R Schneider-Stock
-
Translational Therapeutics
| Open AccessInhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
- G O'Boyle
- , I Swidenbank
- & P E Lovat
-
Molecular Diagnostics
| Open AccessTyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients
- P El Hajj
- , F Journe
- & G Ghanem
-
Molecular Diagnostics
| Open AccessBRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
- J S Wilmott
- , A M Menzies
- & G V Long
-
-
Translational Therapeutics
| Open AccessMacrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
- E Girard
- , C Strathdee
- & C Quéva
-
Translational Therapeutics
| Open AccessThe fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
- F Seguin
- , M A Carvalho
- & E Graner
-
Clinical Study
| Open AccessSerum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
- B Weide
- , M Elsässer
- & C Garbe
-
Clinical Study
| Open AccessSorafenib in advanced melanoma: a critical role for pharmacokinetics?
- N Pécuchet
- , C Lebbe
- & F Goldwasser
-
Epidemiology
| Open AccessBreslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients
- S Kruijff
- , E Bastiaannet
- & H J Hoekstra
-
-
Clinical Study
| Open AccessA phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- D S Boss
- , H Glen
- & T R J Evans